Cardinal Health price target raised to $91 from $78 at UBS

UBS analyst Kevin Caliendo raised the firm’s price target on Cardinal Health to $91 from $78 and keeps a Buy rating on the shares as part of a broader research note on pharma distributors. The analyst contends that Pharma distribution is a relative safe haven while noting "stable" Rx trends and positive channel checks around brand and generic drug inflation.